Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1838)
•••
Comment by lscfaon Feb 14, 2024 3:26pm
108 Views
Post# 35880475

RE:RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024

RE:RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024Co. needs to do $30 million/yr revenue to justify current share price 



 

Revenue

30,000,000

50% gross margin

15,000,000

Cash Overhead

-10,000,000

ebitda

5,000,000

Diluted shs

181,285,742

Ebitda/sh

$0.0276

Multiple

15

Sh value

$0.41

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities